NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a publicly traded biotech company's Phase 2 clinical program. This new client, needing biologic manufacturing for a Phase 2 clinical program under cGMP guidelines, will benefit from Scorpius' comprehensive services in process development, bioanalysis, and manufacturing. The client, transitioning from a large CDMO, chose Scorpius to assist in this Phase 2 program based on adaptability, dedicated service, and commitment to meeting project timelines.

The scope of work, which includes producing a monoclonal antibody (mAb) in Scorpius' mammalian facility, is expected to be completed in 2024.